Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)

Sponsor
Ruijin Hospital
Study ID
NCT06534463
Status
Recruiting
Apply to this trial

Conditions

  • Marginal Zone Lymphoma

Eligibility Criteria

Sex
ALL
Age
14 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China. — OTHER
    The dosage and duration of any drug in this study will be determined by the physician based on local clinical practice and local drug labels. The drugs in this study include, but are not limited to, Obinutuzumab, Rituximab, Bruton tyrosine kinase inhibitors, and Lenalidomide. In this non-interventional study, all treatment drug usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.

Study Details

This study aims to evaluate real-world treatment modalities and their corresponding effectiveness and safety in Chinese patients with marginal zone lymphoma, while also exploratively analyzing patient characteristics and health-related quality of life.

Key Dates

First listed
Aug 2, 2024
Start date
Aug 2, 2024
Status verified
Nov 2024
Primary completion
Mar 1, 2029
Completion
Sep 1, 2029

Study Design

Enrollment
500 participants (estimated)

Arms

  • Arm: Observational Cohort
    Including newly diagnosed marginal zone lymphoma (MZL) and relapse/refractory MZL participants who meet the treatment indications for MZL and are about to undergo MZL treatment.

Primary Outcome Measure

Progression-free survival [ Time Frame: Baseline up to data cut-off (up to approximately 60 months) ]

Central Contacts

Related Studies